Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 


 
 Table of Contents  
ORIGINAL ARTICLE
Year : 2014  |  Volume : 10  |  Issue : 1  |  Page : 38-42

A single institution retrospective analysis of malignant melanoma


Department of Radiation Oncology, Oncology Hospital of Ankara, Mehmet Akif Ersoy Street, Yenimahalle, 06105, Ankara, Turkey

Date of Web Publication23-Apr-2014

Correspondence Address:
Aytul Ozgen
Department of Radiation Oncology, Oncology Hospital of Ankara, Mehmet Akif Ersoy Street, Yenimahalle, 06105, Ankara
Turkey
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0973-1482.131356

Rights and Permissions
 > Abstract 

Background: The incidence of melanoma is rising at a rate greater than any other malignancy, although much of this increase is due to the more frequent diagnosis of patients with the earlier stages of melanoma.
Objective: In this study, patient and tumor-related characteristics and their effects on survival were evaluated.
Materials and Methods: The data was drawn from the patients' records with histologically proven primary cutaneous melanomas treated at the Ankara Oncology Hospital between January 2003 and December 2010. Sixty-nine patients (48 men and 21 women) were included in this study. 17 of the patients had already distant metastases at the time of diagnosis. While 45 of all patients had undergone surgery alone, 17 had received only palliative radiotherapy, and 7 had received primary radiotherapy. Survival curves were determined from the time of diagnosis.
Results: A total of 69 cutaneous melanoma cases were evaluated. While there was a predominance of males in all body sites, especially in the head and neck regions, the number of male patients was 5 times higher than females. Diseases located on the head tended to present a significantly higher rate in older patients (P = 0.009). Overall survival rates for 1 and 3 years were 79% and 44%, respectively. Distant metastatic melanoma was significantly related with poor prognosis (P < 0.001). Anatomic location showed a borderline significancy as a prognostic factor for overall survival (P = 0.053).
Conclusion: Cutaneous melanomas developing at different body sites are associated with distinct patterns of survival outcomes. In this retrospective analysis, melanomas of the head and neck and limb, which are regional melanoma, appear to have better survival outcomes.

 > Abstract in Chinese 

单中心恶性黑色素瘤回顾性分析
背景:恶性黑色素瘤的发病率比其它恶性肿瘤增长显著,虽然此增长多归因于早期恶黑病人的确诊。
目的:本文主要评估病人和肿瘤相关特征及它们对生存期的影响。
材料和方法:数据来源于安卡拉肿瘤医院2003.1~2010.12的组织学证实的原发性皮肤恶性黑色素瘤的病例。包括69病例(48男,21女)。17例在确诊时已有远处转移。45例仅施行手术,17例仅行姑息放疗,7例行根治性放疗。生存曲线从确诊开始计算。
结果:共评估69例皮肤恶黑病例。男性占主导,男性病例数量是女性的5倍,身体任何部位都可发病,尤其在头颈区域。头面部的恶黑在老年病人中显著(P=0.009)。总体1年和3年生存率为79%和44%,另外,远处转移者预后显著差(P<0.001)。解剖学位置在整体生存率提示显明分界线(P=0.053)。
结论:皮肤恶性黑色素瘤发生于不同身体部位提示明显的生存结果差异。本次回顾性分析中,位于头、颈、四肢的区域性黑色素瘤,生存结果优于其它。
关键词:年龄,性别,恶性黑色素瘤,生存期


Keywords: Age, gender, malignant melanoma, survival


How to cite this article:
Ozgen A. A single institution retrospective analysis of malignant melanoma. J Can Res Ther 2014;10:38-42

How to cite this URL:
Ozgen A. A single institution retrospective analysis of malignant melanoma. J Can Res Ther [serial online] 2014 [cited 2019 Oct 14];10:38-42. Available from: http://www.cancerjournal.net/text.asp?2014/10/1/38/131356


 > Introduction Top


In Europe, the incidence of melanoma has been increasing steadily since the 1950s with a great geographical disparity. [1]

Melanoma is a malignant tumor that originates from melanocytic cells and primarily affects the skin. The most essential exogenous etiological factor is exposure to ultraviolet radiation although the relationship between risk and exposure is complex. [2] Different studies have shown that the pattern of exposure has changed in recent decades from effectively occupational to effectively recreational sun exposure, thus influencing the incidence of melanoma in developed countries. [3] Besides, the decreased rates of incidence in young adults with melanoma in northern European countries and increased mortality rates in patients with melanoma in eastern and southern parts of Europe were described in 2003. [4]

Diagnosis of melanoma is established by its clinical features, and the A-B-C-D rule is helpful in identifying suspicious pigmented lesions for melanoma (Asymmetry, Border irregularity, Color inhomogeneous, and Diameter more than 5 mm). Almost 90% of melanomas are diagnosed as primary tumors without any evidence of metastasis. The tumor-specific 10-year survival rate for such cases is between 75%-85%. The most crucial prognostic factors for primary melanoma without metastases are vertical tumor thickness (Breslow depth) as measured on the histological specimen; existence of histopathologically recognised ulceration; primary tumor mitotic rate and identification of micro metastases in the regional lymph nodes via sentinel lymph node biopsy. Melanomas can metastasize either via the lymphatic or hematogenous routes. Almost two-thirds of metastases are originally bound to the drainage area of regional lymph nodes.

Although very few developments have been recorded in the treatment of melanoma, survival rates have improved significantly in developed countries. [5] It is thought that this improvement was due to increased public awareness of the effects of excessive sun exposure, as well as earlier detection of melanoma, thus diagnosing thinner tumors.

The aim of this study is to evaluate the incidence and survival of patients diagnosed with melanoma from 2003 to 2010 in our center.


 > Materials and Methods Top


The data was drawn from patients' records with histologically proven primary cutaneous melanomas treated at the Ankara Oncology Hospital from January 2003 to December 2010. Both the patients' folders and our electronic database system were used for data collection. A total of sixty-nine patients with cutaneous melanoma have been treated between these dates and all of them had follow-up data.

Clinical details including location, histopathological features and tumor thickness were assessed by histopathological examinations. Primary tumor location was exhibited with the use of ICD-10 (International Classification of Disease, 10 th revision) and cases were categorized according to the site of the tumor in the head and neck, trunk, extremities and overlapping (WHO) [6] Melanoma subtype was determined according to Clark with the categories a) superficial spreading melanoma (SSM), b) nodular melanoma (NM), c) lentigo maligna melanoma (LMM) and d) acral lentiginous melanoma (ALM). Tumor thickness was measured in millimeters as reported by Breslow.

Patient and tumor-related characteristics (age, gender, primary anatomic site) and their relation to each other were examined. The influence of age was analyzed by categorizing the cohort into two age groups: ≤50 years, and >50 years. The American Joint Committee on Cancer (AJCC) staging system (7 th edition) was applied for either clinical or pathological staging. [7] For externally referred patients without pathological evaluation of the Breslow thickness, clinical stages were defined based on the available T-category, regional lymph node involvement, as well as status of distant metastasis. Stage was grouped into two categories; (1) regional melanoma: stage I, stage II, regional metastatic melanoma (stage III) defined as any stage without distant metastatic disease and (2) distant metastatic melanoma (stage IV) as any stage with distant metastases.

While twenty-four patients were treated with radiotherapy; forty-five patients were treated with only surgery. Of the 24 patients who received radiotherapy, 7 had received primary radiotherapy and 17 had received radiotherapy with palliative intent. [Table 1] lists patient and treatment characteristics. Seven patients received radiotherapy with 6-12 MV megavoltage linear accelerator, and seventeen patients received radiotherapy with 60Co photon beam. Primary tumor and, if present, lymph node metastases were involved in the treatment field. Median radiotherapy dose for patients treated with primary radiotherapy was 46 Gy and for palliative radiotherapy was 30 Gy.
Table 1: Patient and treatment characteristics

Click here to view


Survival curves were determined from the time of diagnosis of primary melanoma, and deemed censored for patients alive at last follow-up or deceased without evidence of melanoma. Univariate analyses of end points for survival were achieved by using the Kaplan-Meier method and the log-rank test. SPSS 13 was used for statistical analysis. For the survival analyses, the following variables were included: Sex (male, female), age (≤50, >50 years), location of the melanoma (extremities, trunk, head and neck), clinically identified regional lymph node metastases (+,-), clinically identified distant metastases (+,-), and distant metastases (brain, lung, bone, and multiple). The Pearson Chi-squared test was performed to investigate associations between the different patient and tumor characteristics. A value of P < 0.05 was considered significant. In addition, comparison of patient characteristics in two different age categories were analyzed using T test for means and Pearson Chi-squared test for categorical variables.


 > Results Top


Between January 2003 and December 2010, a total of 69 consecutive and non-selected cases of malignant melanoma with pathologic confirmation were established and reviewed.

Of the 51 patients for whose tumors' Breslow thickness was measured, the mean and median Breslow thicknesses were 3.5 mm and 2.5 mm, respectively; whereas in 18 patients, Breslow thickness was not specified in the pathological reports.

Since Breslow thickness was available in 51 of the 69 patients, clinical staging was based on the available knowledge of T-category, regional nodal status, and distant metastasis. Fifty-two patients presented with primary disease based on pathology study but no evidence of regional or distant metastasis were staged as stage I, II disease. A total of 17 patients with regional lymph adenopathy without distant metastasis, and 17 patients with distant metastasis were staged as stage III and stage IV diseases, respectively, according to the AJCC clinical classification for melanoma.

A total of 69 patients (48 males and 21 females) with cutaneous melanoma were evaluated. For all cases, a higher rate of the females were in the age group > 50 compared to the males, but significant differences weren›t observed [Figure 1] (P = 0.98). The results were as follows: Rate of females: ≤50 = 42.9%, >50 = 57.1%. Rate of males: ≤50 = 44.2%, >50 = 55.8%. A higher rate of the males were in the age group > 50 compared to the age group of ≤ 50. In this study population, in all disease sites, there was a male predominancy. Between female patients the disease presented on the overlapping areas (43%) was more than other locations (limbs 24%, H + N 19%) [Figure 2]. At the time of diagnosis females were more likely to have distant metastatic melanoma than males (33% of females vs. 21% of males), but did not differ significantly [Figure 3] (P = 0.27). Also, the diseases located on the head and neck areas tended to present significantly in older patients (P = 0.009) [Figure 4].
Figure 1: Variations in age groups at diagnosis and by gender

Click here to view
Figure 2: Gender variations in the anatomic area of disease. (H + N: head and neck, nos/overlapping: not otherwise specified (nos) or overlapping areas)

Click here to view
Figure 3: Gender variations in stage of disease

Click here to view
Figure 4: Correlation between anatomical area and age of patients. (H + N: head and neck, nos/overlapping: not otherwise specified (nos) or overlapping areas)

Click here to view


After treatment, regional lymph node metastases outside the treatment field and distant metastases developed in 9 patients (13%) and 33 patients (48%), respectively. [Figure 5] shows overall survival of all patients. Most of the regional lymph node metastases and distant metastases developed within 2 years after the initial treatment. Overall survival rates for 1-year and 3-years were 79% and 44%, respectively. Overall survival rates for 1-year and 3-years of treatment with surgery alone were 88% and 74%, respectively.
Figure 5: Overall survival of all patients

Click here to view


The results of univariate analysis for overall survival are shown in [Table 2]. Distant metastatic melanoma was significantly related to worse prognosis (P < 0.001) [Figure 6]. Anatomic location showed borderline significance as a prognostic factor for overall survival (P = 0.053) [Figure 7]. The disease located on the trunk tended to relate worse prognosis. None of the other factors were found to be effective on overall survival.
Figure 6: The effect of distant metastases on survival

Click here to view
Figure 7: The effect of anatomical area on survival. (H + N: head and neck, nos/overlapping: not otherwise specified (nos) or overlapping areas)

Click here to view
Table 2: Univariate analysis of overall survival

Click here to view



 > Discussion Top


Using data from southern European countries, [8] a rising trend in melanoma mortality has been reported. We constructed a retrospective study for the risk of melanoma incorporating traditional epidemiologic risk factors. We want to highlight a significant increase in both incidence and mortality in our country for greater awareness of the impact of early diagnosis of melanoma on the quality of life. Referral rates in our country vary according to geography and gender. Fewer referrals were observed in areas where there is less access to a major cancer center. Fewer referrals were also observed for females.

SEER data between 1999 and 2001 demonstrated an increased incidence of melanoma by age. [9] The data also showed the same incidence of melanoma for women and men up to 49 years of age, and a higher incidence of melanoma for men than women at ages older than 50 years. We found a similar incidence of melanoma for women and men for all ages.

As noted in other studies, the anatomic incidence of melanoma varies between the two genders. Presentation differs between the genders, with men more likely to present with melanomas on the trunk, whereas women tend to have a disease on the lower limbs. [10],[11] In our study, diseases located on the head and neck tended to present in males (83%), and diseases located on the trunk and limbs also tended to present in males (67% and 69%, respectively). The referral rates for each gender were different, with 70% of males and 30% of females referred to the hospital. This may explain the differences between the two genders for trunk and limbs according to the literature.

A study from England showed that several factors had a negative impact on survival, including having a tumor located on the trunk and being male. [12] We observed the same negative impact on survival from having a tumor located on the trunk. Whereas both incidence and mortality are decreasing in younger age groups, rates are still increasing in older age groups. [13],[14] The continuous downward trend of the tumor thickness was observed during the time period in all age classes by Buettner and his group. [15] Nevertheless, tumor thickness remained higher in the older age group than in the younger age group. Older patients had greater possibility for accumulating high levels of sun exposure. This may explain the higher mortality rates in the older age group. We didn't find the same significance for survival in our age groups. However, as in the literature, [16] we did observe that melanoma was located predominantly on the head and neck and occurred later in life.

The growth of distant metastases after treatment is a serious problem associated with this disease. A study by Mandolis et al., demonstrated the average distant metastasis rate after treatment to be 51.5%. [17] In the present study, the 2-year distant metastasis-free survival rate was 50%, and most distant metastases were detected within 2 years following the initial treatment.

Patient and tumor related characteristics of malignant melanoma diagnosed in our institute was the focus of the study. Demographical patterns of melanoma in Turkey are similar compared with the general literature data from Western countries [18],[19] One of the interesting issue that needs further research is the influence of sunlight to the incidence of cutaneous melanoma in Turkey. Currently, there is not enough epidemiologic research reported from Turkey in region wise that has addressed the cause-effect relation between sun exposure and cutaneous melanoma. In addition, a regional statistical investigation and active planning to address the epidemiology of malignant melanoma more effectively are needed.

We feel it is possible, as other authors [20] have observed, that the increase in the rate of early stage incidence cases is the result of the adoption of new screening and diagnostic practices and greater awareness of the impact of early melanoma diagnosis on the quality of life. Enhanced public awareness about the consequences of excessive exposure to the sun and the use of better sun protection may lead to a decrease in melanoma cases.

 
 > References Top

1.DeVries E, Bray Fl, Coebergh JW, Parkin DM. Changing epidemiology of malignant cutaneous melanoma in Europa 1953-1997: Rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia. Int J Cancer 2003;107:119-26.  Back to cited text no. 1
    
2.Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-47.  Back to cited text no. 2
    
3.Armstrong B. Epidemiology of melanoma and current trends In: Thompson JF, Morton DL, Kroon BB, editors. Text book of melanoma. London: Martin Dunitz; 2004. p. 65-80.  Back to cited text no. 3
    
4.DeVries E, Coebergh JW. Melanoma incidence has risen in Europe. Br Med J 2005;331:698.  Back to cited text no. 4
    
5.Gibin AV, Thomas JM. Incidence, mortality and survival in cutaneous melanoma. J Plast Reconstr Aesthet Surg 2007;60:32-40.  Back to cited text no. 5
    
6.WHO. ICD-10: International Statistical Classification of disease and related health problems, 10 th revision, 2 nd ed. Geneva: WHO; 2005.  Back to cited text no. 6
    
7.Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-206.  Back to cited text no. 7
    
8.Severi G, Giles GG, Robertson C, Boyle P, Autier P. Mortality from cutaneous melanoma: Evidence for contrasting trends between populations. Br J Cancer 2000;82:1887-91.  Back to cited text no. 8
    
9.Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the Surveillance, Epidemiology and End Results (SEER) program. Oncologist 2003;8:541-52.  Back to cited text no. 9
    
10.Hall H, Miller D, Rogers J, Bewerse B. Update on the incidence and mortality from melanoma in the United States. J Am Acad Dermatol 1999;40:35-42.  Back to cited text no. 10
    
11.MacKie R, Bray C, Hole D, Morris A, Nicolson M, Evans A, et al. Incidence of and survival from malignant melanoma in Scotland: An epidemiological study. Lancet 2002;360:587-91.  Back to cited text no. 11
    
12.Newnham A, Moller H. Trends in the incidence of cutaneous malignant melanomas in the South east of England, 1960-1998. J Public Health Med 2002;24:268-75.  Back to cited text no. 12
    
13.Bevona C, Sober A. Melanoma incidence trends. Dermatol Clin 2002;20:589-95.  Back to cited text no. 13
    
14.Marks R. The changing incidence and mortality of melanoma in Australia. Recent Results Cancer Res 2002;160:113-21.  Back to cited text no. 14
[PUBMED]    
15.Buettner PG, Leiter U, Eigentler TK, Garbe C. Development of prognostic factors and survival in cutaneous melanoma over 25 years: An analysis of the Central Malignant Melanoma Registry of the German Dermatological Society. Cancer 2005;103:616-24.  Back to cited text no. 15
    
16.Lee EY, Williamson R, Watt P, Hughes MC, Green AC, Whiteman DC. Sun exposure and host phenotype as predictors of cutaneous melanoma associated with neval remnants or dermal elastosis. Int J Cancer 2006;119:636-42.  Back to cited text no. 16
    
17.Mandolis S, Donald PJ. Malignant mucosal melanoma of the head and neck: Review of the literature and report of 14 patients. Cancer 1997;80:1373-86.  Back to cited text no. 17
    
18.Tas F, Kurul S, Camlica H, Topuz E. Malignant melanoma in Turkey: A single institution′s experience on 475 cases. Jpn J Clin Oncol 2006;36:794-9.  Back to cited text no. 18
    
19.Uysal-Sonmez O Tanrýverdi O, Esbah O, Uyeturk U, Helvaci K, Bal O, et al . Multicenter evaluation of patients with cutaneous malignant melanoma in Turkey: MELAS study. Asian Pac J Cancer Prev 2013;14:533-7.  Back to cited text no. 19
    
20.Lipsker DM, Hedelein G, Heid E, Grosshans EM, Cribier BJ. Striking increase of thin melanomas contrasts with the stable incidence of thick melanomas. Arch Dermatol 1999;135:1451-6.  Back to cited text no. 20
    


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6], [Figure 7]
 
 
    Tables

  [Table 1], [Table 2]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  >Abstract>Introduction>Materials and Me...>Results>Discussion>Article Figures>Article Tables
  In this article
>References

 Article Access Statistics
    Viewed1588    
    Printed77    
    Emailed1    
    PDF Downloaded116    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]